Genetically modified foods in China and the United States: A primer of regulation and intellectual property protection  by Wong, Alice Yuen-Ting & Chan, Albert Wai-Kit
Am
t
a
C
t
©
1
g
h
N
o
fi
m
p
h
fi
F
W
a
h
2Available online at www.sciencedirect.com
ScienceDirect
Food Science and Human Wellness 5 (2016) 124–140
Genetically modified foods in China and the United States: A primer of
regulation and intellectual property protection
Alice Yuen-Ting Wong a,∗, Albert Wai-Kit Chan b,c
a Albert Wai-Kit Chan Intellectual Property Limited, Hong Kong Special Administrative Region
b United States-China Intellectual Property Institute, New York, USA
c Law Ofﬁces of Albert Wai-Kit Chan, PLLC, New York, USA
Received 6 February 2016; accepted 17 March 2016
Available online 24 May 2016
bstract
Food is a basic and personal necessity to human. Safety of food is a prime factor to consider apart from nutrition, quality and cost. Genetically
odified (GM) foods first came on the market in 1994. Yet safety, transparency and traceability of GM foods are still under hot debate. Nonetheless,he market of GM foods is huge and attractive. Regulatory affairs and intellectual property (IP) are two critical factors affecting the development
nd commercial success of a food product. This article will take a look at the GM food technology and regulatory framework for GM foods in
hina and the United States. This article will also discuss the unique patent issues and non-patent IP tools for safeguarding the technology in these
wo countries.
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. Introduction
Genetically modified organisms (GMOs), also known as
enetically engineered or transgenic organisms, for use as
uman foods or animal feeds are commonplace nowadays. On
ovember 19, 2015, the Food and Drug Administration (FDA)
f the United States approved the first-ever genetically modi-
ed animal for human consumption [1]. This approval not only
arked a new milestone for GM foods but also re-evoked the
ublic call for safety assessment and transparency of GM foods.
The advances in recombinant DNA technology in the 1980s
ave led to the creation of GM foods. FlavrSavr® tomato, the
rst GM food approved for human consumption in the world,
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ntered the U.S. market in 1994 as fresh tomato and reached
he United Kingdom in 1996 in the form of tomato paste [2].
ince then, the market of GM foods has grown rapidly and keeps
xpanding. Many food products currently on our shelves are
erived from GM organisms or contain GM ingredients. Most
M foods are produced from plants, but GM microorganisms or
M animals have also been used to produce food products such
s yogurt and cheese [3]. GM crops are now widely cultivated
hroughout the world. In 2014, approximately 18 million farmers
n 28 countries planted GM crops in more than 181 million
ectares, corresponding to 13% of the world’s arable surface
4,5]. Globally, GM soybeans accounted for about 82% of the
otal soybean area, while GM cotton, maize and oilseed rape
ccupied 68%, 30% and 25% of the total crops area respectively
4].
Approximately 70%–90% of GM crops are used as feeds for
ood-producing animals [4]. Foods produced from these GM
ood-fed animals are not regulated or labeled as GM foods in
ost if not all countries [6]. Therefore, consumers may unknow-
ngly consume GM ingredients even if they actively avoid GM
oods.As of October 2014, 65 countries have granted regulatory
pprovals to GM crops for use as foods, feeds or for environ-
ental release, encompassing a total of 27 types of GM crop
lsevier B.V. All rights reserved.
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nd 357 GM events [5]. Most countries permit the production
nd marketing of GM organisms except a few such as Russia,
orway, Netherland and Israel, but require an official approval
n advance. Among those permissive countries, China, France,
ew Zealand and South Korea appear to be more restrictive as
hese countries so far have issued no or few permits to GM crops
or commercial cultivation [6].
While for GM foods, production and marketing are gen-
rally permitted; many countries do not mandate a labeling
f GM foods [6]. The European Union (EU) imposes stricter
pproval and labeling requirements for GM foods, demanding
risk assessment for all new GM foods and feeds before mar-
eting and a compulsory labeling of GM foods. Following the
U law, many European countries such as the United Kingdom,
weden, Norway and Germany now require foods containing or
roduced from GMOs, or containing ingredients produced from
MOs be clearly labeled. However, foods produced with GM
echnology such as recombinant enzymes, or from animals fed
ith GM foods are exempted [6].
Available scientific findings seem to be in favor of the safety
f GM organisms. Remarkably, a few U.S. scientific organi-
ations have concluded that there is no evidence showing GM
rganisms are risker than, or present unique safety risks than
he conventional organisms [6]. However, the public has not
uilt sufficient confidence in GM foods and generally desires
hat GM foods be adequately labeled. It is postulated that the
ack of objective information about the risks and benefits of GM
oods may account for the consumers’ skeptical attitude to GM
oods [4]. For instance in the U.S., a survey interviewed 2002
dults and 3748 scientists from the American Association for
he Advancement of Science (AAAS) revealed that 88% of the
cientists think that GM foods are safe for eating compared with
nly 37% of the general public [7]. The public even thinks that
cientists do not have a clear understanding of the health effects
f GM foods [4].
There are mounting evidences supporting GM foods are safe.
n 2013, Nicolia et al. published a study which systematically
eviewed a total of 1783 scientific papers on the safety of GM
rops published from 2002 to October 2012. This report con-
luded that there is no evidence showing the use of GM crops
as posed significant hazards to the environment and human
8]. Verma discussed some common public concerns over GM
oods such as risks to health, spread of transgene and negative
mpacts on ecosystem, concluding that many of these concerns
re hypothetical and not substantiated by scientific grounds [9].
awa et al. reviewed a number of safety assessment reports on
ommon commercial GM crops such as tomato, soybean and
aize. The authors noted a few findings indicated that there
re differences in terms of protein production and morpholog-
cal observations between animals fed with GM varieties and
nimals fed with conventional varieties, but pointed out that in
hese studies the methodology was not properly designed or the
ata could not sufficiently support the finding that transgenic
pecies are more toxic than the conventional species [10].
On the other hand, focusing on long-term rat feeding studies
f GM crops that are no less than 90 days of duration, Zdziarski
t al. reviewed 21 published articles investigating the effects
f
b
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f GM crops containing one or more of three common foreign
raits on the gastrointestinal tract of rats. The authors found that
any of these studies did not provide sufficient details of their
ethodology, results or any definition of toxicity or signs of
athology, and concluded that all these studies are significantly
nadequate or flawed to demonstrate the toxicity and safety of
he tested GM crops for human and animal consumption [11].
onetheless, the above reviewers concurred that case-by-case,
igorous and detailed scientific studies assessing the risks of GM
oods to human and animals are essential to provide objective
cientific information for consumers to thoroughly understand
M foods and to minimize the adverse impacts from GM foods.
United States and China are two large markets of GM foods.
n 2014, the U.S. grew the largest area of GM crops, followed
y Brazil and Argentina [4]. GM soybean, maize and cotton are
xtensively adopted, respectively accounting for 94%, 93% and
6% of the total crops area in 2014 [4]. China is the biggest grain
onsumer, taking up one-third of the global soybean production.
he country ranked the sixth in terms of the cultivation area of
M crops in 2014 [4]. It was estimated that nearly 95% of all
mported maize and over 90% of the imported soybean of China
re genetically modified [4].
Legislation and regulation for GM organisms and foods in
he U.S. and China are on the horizon. Recently in July 2015,
he U.S. government announced its plan to revise its 30-year-old
egulatory system over GM crops and some other biotechnol-
gy products [12]. While in China, the Ministry of Agriculture
MOA) intends to strengthen research on the technology of agri-
ultural GMOs as well as the safety assessment, regulation and
anagement of agricultural GMOs [13].
While regulatory affairs are important to the development
nd commercialization of GM food products, intellectual prop-
rty (IP) is another key factor for paving the way to success.
P serves a fundamental role in protecting innovators’ interest
y preserving the exclusive right in their inventions, meanwhile
an be monetarized through various transactions such as invest-
ent, licensing, technology transfer to foster future research and
evelopment. This article will provide an overview of the cur-
ent regulatory framework concerning GM foods in China and
he United States. We will also take a look at the patent land-
cape and non-patent options in these two countries as a guide
o IP protection for the GM food technology.
. Genetic engineering and food
Thanks to the advancements in recombinant DNA technol-
gy, we can now modify the genetic makeup of organisms.
ecombinant organisms were created in 1970s and have been
idely applied in the agricultural and pharmaceutical industries,
roducing GM foods and therapeutic proteins such as growth
ormones, vaccines and antibodies.
Defined by the World Health Organization (WHO), geneti-
ally modified (GM) or genetically engineered (GE) foods are
oods derived from organisms in which genetic material has
een altered in a way that does not occur naturally by mating
nd/or natural recombination [3]. Transgenic organisms are usu-
lly created by inserting a foreign gene into the genome or cells
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f an organism using virus, gene gun or direct injection into
he nucleus. Technologies such as intragenesis and cisgenesis
re available to transfer a gene from the same or close species
14]. It is also possible to modify genetic sequences without
nserting foreign materials into the organism for example using
he Clustered Regularly-Interspaced Short Palindromic Repeats
CRISPR) system.
With limited natural resources such as land, water and energy,
ood security is not limited to developing countries but a global
ssue. The Food and Agriculture Organization of the United
ations (FAO) issued a report in 2011, estimated that almost
ne-third of food produced for human consumption (about 1.3
illion tons per year) was either lost or wasted [15]. Minimizing
ood loss is a must, while having a sustainable food produc-
ion is another way to satisfy the global food demand. Food
rops occupy a substantial portion in human and animal diet.
xtreme weather, pests, weeds and crop diseases could impose
etrimental effects to crops and significantly reduce their yields.
esticides, herbicides and chemical fertilizers have long been
sed to enhance the production, however, drawbacks such as
ischarges of noxious or polluting ingredients and weakened
ffectiveness upon prolong use undermine their long-term use.
New variety of crops endowed with desired properties can
e created through genetic engineering. For instance, with the
ew traits, crops could survive better in extreme climate such as
rought and cold, or become more tolerant to pathogen-borne
iseases or to pest, insect or weed killers. Accordingly, crops can
e produced at higher yields and even be marketed at lower prices
3]. Crops can also be modified to synthesize pesticides in their
ody so that farmers can reduce their use of pesticides. Accord-
ng to a meta-analysis reviewed 147 GM crop studies released
rom 1995 to March 2014, the adoption of GM technology in
rop cultivation has reduced the use of chemical pesticides by
7%, increased crop yields by 22%, and increased farmer pro-
ts by 68% on average [16]. Beyond profitability, farmers also
ave time and labor in weed control and have more flexibility in
lanning the cultivation [4]. Nutritional value, flavor and shelf
ife can also be improved by genetic engineering.
. Examples of GM crops
.1. Biopesticides
Bacillus thuringiensis (Bt) is a soil bacterium that has been
idely used as a natural pesticide in agriculture since 1920s. Bt
roduces Crystal (Cry) proteins which can paralyze the pest’s
igestive system by inducing pores in cell membrane of the gut
pithelial cells and in turn kill the pests, whilst remain safe to
uman because human does not have the equivalent receptor
n the gut. Cry proteins are traditionally sprayed on crops but
re susceptible to degradation under sunlight. Also, since Cry
rotein sprays could not reach underground and internal parts of
he plants, the sprays are ineffective in eradicating pests living
n those regions. To confer a long-term and thorough protection
gainst pests, crops are engineered with Bt gene so that they can
xpress the Bt toxins themselves for killing the pests [17]. GM
otato and corn expressing Cry proteins were first approved for
G
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ommercial production in 1995–1996 in the U.S. and are now
lanted worldwide [18,19].
.2. Glyphosate-resistant crops
Glyphosate, a common ingredient found in herbicides,
s able to kill weeds effectively by halting the shiki-
ate pathway responsible for the biosynthesis of aromatic
mino acids. Glyphosate blocks the shikimate pathway by
inding to and inhibiting one of the catalyzing enzymes
alled 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase,
nd eventually kills the organism from the deficiency of essen-
ial aromatic amino acids [20]. Roundup® is one representative
lyphosate-based herbicide developed by Monsanto. The com-
any discovered that a strain of Agrobacterium tumefaciens CP4
ould survive in a glyphosate production facility by producing a
lyphosate-insensitive variant of EPSP synthase. The discovery
ed to the development of glyphosate-resistant Roundup Ready®
rops which are modified with the gene encoding the glyphosate-
nsensitive variant of EPSP synthase. It is also possible to
reate glyphosate-resistant crops using a glyphosate-degrading
nzyme encoding gene [20,21]. Roundup Ready® seeds includ-
ng soybean, cotton, canola and corn seeds have been widely
istributed. Notably in March 2015, the WHO’s International
gency for Research on Cancer (IARC) classified glyphosate
n Category 2A (meaning that glyphosate is probably carcino-
enic to human). The agency opines that there are convincing
vidence showing glyphosate can cause cancer in laboratory
nimals, and glyphosate has been reported to cause DNA and
hromosomal damage in human cells [22]. However later in
ovember 2015, the European Food Safety Authority (EFSA)
oncluded that glyphosate is unlikely to pose a carcinogenic
azard to human [23]. One possible reason for the different con-
lusions is that the EFSA evaluation was conducted based on a
arge body of evidence including a number of studies that were
ot assessed by the IARC [23].
. Safety and risks of GM organisms and foods
As discussed in the introductory session, scientific evidence
s inclined to conclude that GM foods are safe for consumption.
afety, risks and concerns over GM foods and crops have been
iscussed in many reviews [4,8–11]. Without going into details,
he following sessions serve a brief summary of these aspects.
.1. Human health
Whether or not GM foods are safe for human consumption is
he leading subject of public controversies. Consumers desire
o know about the transient and long-term effects to human
ealth upon consumption; among them, allergenicity, toxicity
nd spread of transgene are commonly concerned.
The unpredictable and hidden effects of foreign genes to the
M organisms and consumers may be one underlying reason
or the public disquiet. First at the gene level, it is unpredictable
hether the new genetic material will be exclusivity and pre-
isely incorporated into the target site, and whether the genetic
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aterial will interfere with the recipient’s biological system and
roduce any effects beyond expectation. It has been demon-
trated that DNA fragments from high-copy number genes can
ass across through the gastrointestinal tract and go to internal
rgans, tissues and blood of different animals [8], implicating a
hance of incorporating foreign DNA into the consumers’ cells.
owever, the incidence that the DNA absorbed through the gut
ould integrate into the host organism is believed to be really low,
iven that the DNA intake from diet is as low as about 0.1–1 g
er day and the consumed DNA is digested and diluted in the
onsumer body. So far there is no evidence showing the foreign
ene absorbed from the gut can integrate into consumer’s cells
nd lead to a germ line transfer [8].
At the protein level, the modifications may lead to new aller-
ens or toxins that cannot be identified by current methodologies
hat screen for known toxins and allergens, and could put human
ealth at risks. So far two GM crops have been reported on the
otential allergenicity of transgenic protein. The first one is a
oybean introduced with the gene encoding methionine-rich 2S
lbumin from the Brazil nut for improving the methionine con-
ent of the soybean. Subjects that were allergic to Brazil nuts
eveloped positive reactions to extracts of transgenic soybean
ut negative reactions to extracts of non-GM soybean in skin-
rick tests [24]. The second case is the StarLink corn engineered
ith a Bt protein Cry9C. StarLink was only approved for ani-
al feed in the U.S. in 1998 but was later discovered in tacos
nd tortillas in September 2000. The FDA received 51 reports of
dverse reaction to these corn products and among them 28 indi-
iduals appeared to develop allergic reactions. However, the U.S.
enters for Disease Control (CDC) found no conclusive evi-
ence of hypersensitivity to the Cry9C protein in these subjects
25]. Nonetheless, the developer Aventis voluntarily withdrew
he registration for StarLink corn in October 2000.
There are also animal studies reporting that consumption of
M foods may lead to disruption to kidneys and livers, higher
ates of infant mortality and infertility problems [26,27], but
ore tests are needed for verification.
.2. Wild life and environment
Impacts and risks of GM organisms to the environment
ay be more apparent than to human health. Some common
nvironmental concerns include a reduction of biodiversity,
ontamination of wild species, threats to non-target species, out-
reak of antibiotic resistant bacterial strains and super-weeds,
nd deterioration of soil and water pollution.
First, it is concerned that the GM technology promotes large
cale monocultures and may reduce the biodiversity [9]. Farm-
rs likely prefer to grow one or few GM varieties having desired
raits, hence GM varieties may become dominant while tra-
itional varieties may be gradually lost. Reliance on limited
arieties may also reduce the emergence of new variety because
he genetic makeup becomes more uniform. However, it should
e noted that the loss of biodiversity can also be attributed by
ther selective breeding non-GM technologies [9,28]. Monocul-
ure of one single crop variety may also increase the vulnerability
f crops to diseases and other environmental challenges [28].
[
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Adoption of GM crops may endanger non-target species in
he environment. For example, Bt protein was reported to be
oxic to non-target insect such as monarch butterflies [28]. How-
ver, the review by Nicolia et al. concluded that there is no
onsolidated scientific evidence showing the negative impacts
f GM crops on the biodiversity of non-target species such as
irds, snakes and soil macro and micro fauna [8].
Genetic drift is another key concern as genes may migrate out
f the GM organism to wild species and even to largely unrelated
pecies. Outcrossing of transgenes to conventional species may
appen and contaminate the wild-type species [9,28]. GM com-
ingling and contamination during post-harvest handling are
ommon and severely impact the organic farmers [21]. Setting
side the crop quality, organic farmers who have their seeds or
rops contaminated with patented GM varieties may be liable for
atent infringement. Notably, after the report of GM contamina-
ion of conventional corn and rice, a few countries such as Japan
nd Europe banned or strictly limited the importation of corn
nd rice from the U.S., causing a significant loss to the farmers
nd the industry [29]. On the other hand, antibiotic resistance
enes that serve as selectable marker genes for selecting trans-
enic cells may pass to bacteria present in the environment or in
he consumers’ gut [3,8,9], although the occurrence is unlikely
iven the extremely low frequency of uptaking exogenous DNA
y bacteria (10−4 to 10−8) [8].
Lastly, it is postulated that the prevalent use of herbicide-
esistant crops would further encourage the use of herbicides and
romote the development of super weeds [9]. Many GM crops
re modified to be glyphosate-resistant, farmers are now less
eluctant to use glyphosate-containing herbicides on their crops.
he repetitive and high-volume use of herbicides has created a
icious cycle worsening the pollution and making weed control
ore difficult. Glyphosate resistant weeds and Bt-toxin resistant
ests have been reported [8].
. Regulation in China
.1. Adoption of GM crops in China
Nurturing nearly one-fifth of the world population but pos-
essing only 6% of fresh water and 7% arable land, food security
s a critical issue to China [30]. China consumes the greatest
ortion of grains and is the largest rice producer and consumer
31]. Currently papaya is the only edible GM plant allowed for
ommercial production in China.
China’s agriculture biotechnology is world-leading and is one
f the major areas that the Chinese government has been pledg-
ng to actively promote. By 2011, it was estimated that over 70%
f the total agricultural biotechnology invention patent were filed
y domestic sectors [31]. As early as 1992, China is the first
ountry permitting the commercialization of GM crop, but the
pproved virus resistant tobacco was revoked from cultivation
few years later because of strong pressure from other regions32]. To this point, China has only approved the commercial
lanting of two GM crops which are a Bt cotton (in 1996) and a
irus resistant papaya (in 2006) [6,33]. The two GM crops are
ow planted with an adoption rate of around 93%–94% [34,35].
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ive types of transgenic crops soybean, corn, cotton, canola and
ugar beet have been permitted for import into China either for
ultivation or as raw materials for processing [6,33]. Besides,
transgenic poplar was approved for commercial plantation in
003 by the State Ministry of Forestry and is the only transgenic
orest tree approved so far [34].
.2. Legislation
China has not enacted any national law specific for GMOs
r GM foods but regulations overseeing agricultural GMOs are
vailable. The Ministry of Agriculture (MOA) and the General
dministration of Quality Supervision, Inspection and Quar-
ntine (AQSIQ) are the two agencies responsible for policing
gricultural GMOs and GM foods.
In the 12th Five-Year Plan on National Economic and
ocial Development for 2011–2015, the Chinese government
xpressed its ambition to speed up the innovation and applica-
ion of biotech breeding in agriculture and to foster a large and
trong modern seed industry [36]. Despite the State’s highly
ermissive policy and plentiful research funding, commercial
rospects of GM crops are not too promising. The less receptive
ttitude of the Chinese population may be one reason for the
overnment’s hesitation in permitting the commercialization of
ransgenic crops [30]. According to an online survey interview-
ng 50,000 people in 2010, about 84% of the respondents would
ot choose GM foods for safety reasons [30].
In early 2015, the Central Committee of the Communist Party
f China and State Council provided 32 concrete suggestions
n how to foster the development of modern agriculture and
ural community and how to increase farmers’ income [37]. The
uthorities emphasize the significance of food security and the
ital role of agriculture in national socioeconomic development,
hile acknowledging the necessity to enhance food safety and
he quality of agricultural products. Among these suggestions,
ne is to reinforce the research on agricultural GMOs, and their
afety management and the general public education about them.
he above reflect the Chinese government’s desire to develop
gricultural GM technology in full force and more importantly
he substantive initiative to look into the public concern over
M foods.
.3. Agency regulations
.3.1. Ministry of Agriculture (MOA)
Promulgated by the State Council in 2002, the GMOs Reg-
lations or formally known as “Regulations on Administration
f Agricultural Genetically Modified Organisms Safety” out-
ine the regulatory framework for research, testing, production,
rocessing, marketing, import and export of agricultural GMOs
38]. The MOA issued four administrative measures regarding
he safety evaluation [39], processing [40], safety control for
mport [41] and labeling [42] of agricultural GMOs to implement
he GMOs Regulations.
These provisions define that agricultural GMOs are animals,
lants or microorganisms of which genomic structures have
een modified by genetic engineering technologies (and their
r
M
o
fnd Human Wellness 5 (2016) 124–140
roducts) which are used in agricultural production or
rocessing. GM foods are subject to these provisions absent
ny specific rules [6], given that the prior two GM food rules
mplemented by the Ministry of Health (MOH) were abolished
n 2007 and 2013 respectively.
Each step of testing, production, processing, import and
arketing of agricultural GMOs must seek an approval from
he MOA. Production and marketing GMOs or GMO products
equire special licenses, and a biosafety certificate is a prerequi-
ite for applying the licenses. For instance, at least four permits
re required for commercial cultivation and marketing a trans-
enic crop, namely a biosafety certificate as a proof of safety to
uman and the environment, a crop variety certificate as a suc-
essful registration of the new crop variety, a production license
or producing the transgenic crop and a marketing license for
arketing the transgenic crop.
.3.1.1. Biosafety certiﬁcate. Biosafety certificate evidences
hat an agricultural GMO has passed the safety assessment con-
ucted by the GMO Biosafety Committee. Under the GMOs
egulations, a biosafety certificate is compulsory for the fol-
owing basket of transgenic organisms and products: transgenic
lanting seeds, livestock and poultry breeds and aquatic fry,
nd planting seeds, livestock and poultry breeds, aquatic fry,
esticides, veterinary drugs, fertilizers, additives and others
roduced using agricultural GMOs or containing agricultural
MOs ingredients.
There are five stages for obtaining a biosafety certification
f a new agricultural GMO, namely (i) laboratory research; (ii)
estricted field trials; (iii) environmental release field trials; (iv)
reproduction testing; and (v) application for a biosafety certifi-
ate. Agricultural GMOs are classified by the MOA into Class I,
I, III or IV according to the extent of their risks to human, ani-
als, plants, microorganisms and the ecological environment.
otification to the MOA must be made before commencement
f research involving Class III or IV GMOs [38].
After laboratory research, the developer may proceed with
he three testing stages successively. The developer needs to
eport to the MOA before starting any restricted field trials, and
ust provide data and information to the MOA for approval
or moving to the next stage. In short, the developer has to fur-
ish a test report issued by a competent inspection organization
n the field of agricultural GM technology, safety management
nd precautionary measures, and report of the previous testing
tage. The MOA will grant a permit for proceeding with the next
tage only if the GMO passes the safety assessment. Upon com-
letion of all the three testing stages, the developer can apply
or a biosafety certificate with a summary report of the prepro-
uction testing. The MOA will make a decision within 20 days
fter receiving the safety assessment report form the Biosafety
ommittee [38].
The biosafety certificate is valid for five years and requires
enewal 1 year before the expiration date. From 2002 to 2012, the
OA has approved 2775 applications for restricted field trials
f GM plants, 459 for environmental release field trials and 317
or preproduction testing, and issued 1830 biosafety certificates
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o seven types of crops [35]. However, until now only cotton and
apaya can be commercially produced and marketed in China.
.3.1.2. Production and marketing license. To commercially
roduce or market an agricultural GMO or product, one or more
icenses from the MOA are required depending on the purpose.
5.3.1.2.1. Production and processing. By law, all new vari-
ty of planting seeds, livestock breeds, poultry breeds and
quatic fry must be evaluated and approved by the Vari-
ty Approval Committee under the competent administrative
epartment of the MOA before popularization. For crops, all
ew variety of rice, wheat, corn, cotton, soybean, canola, and
otatoes must be evaluated by the Crop Variety Approval Com-
ittee under the National Seed Law. The application requires
two-year variety comparison study comprising field trials and
roduction trials. Upon approval, the MOA will issue a crop
ariety approval certificate which the developer would need for
etting a production license from the competent agricultural
dministrative department. Individuals or companies engaged
n the production or processing of agricultural GMOs also need
permit from the MOA or the provincial agricultural administra-
ive department. For farmers who cultivate or breed the GMOs,
ellers of the transgenic seeds or breeds should apply for the
ermit on behalf of the farmers.
5.3.1.2.2. Marketing and advertising. Similarly, a market-
ng license issued by the competent administrative department
f the MOA is essential for marketing transgenic planting seeds,
ivestock breeds, poultry breeds and aquatic fry. Advertising of
MOs requires prior approval from the MOA [38].
.3.1.3. Import into China. Import of agricultural GMOs and
roducts into China can be subdivided into four types (i) import
or research; (ii) import for testing; (iii) import for production;
nd (iv) import as raw materials for processing [41]. Cotton is
he only GMO that can be imported to China for production at
resent, while transgenic soybeans, corn, canola and sugar beets
re imported as raw materials for processing and cannot be used
therwise [35,43].
For research purpose, approval from the MOA is needed for
ll Classes I-IV of agricultural GMOs. For testing, similar to the
omestic route, the applicant has to apply for restricted fields
rials, environmental release and preproduction product testing
n succession. Both research and testing applications require
ocuments evidencing corresponding research or testing have
een conducted outside China [41].
Types (iii) and (iv) would require a biosafety certificate for
mport. For importing the basket of transgenic GMOs and prod-
cts for production, the foreign company needs to seek approval
t the beginning and complete all the three testing phases to
pply for a biosafety certificate. The application also requires
ocuments which indicate the exporting country or region has
ermitted the marketing of the GMOs for the same intended uses,
nd has determined that the GMOs are safe through scientific
xperiments [41].
While for introducing GMOs as raw materials for processing
r directly as consumer goods, procedures for applying a
iosafety certificate are similar to type (iii) except that testing in
v
a
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hina is not required. MOA will appoint a competent inspection
rganization to assess the safety of the subject GMO and issue
certificate upon approval by the GMO Biosafety Committee
41]. For each batch of product imported into China, merchant
eeds to separately apply for a biosafety certificate and furnish
he GMO developer’s biosafety certificate (for import) as a proof
44].
.3.1.4. Labeling. China does not mandate labeling of GM
oods except certain classes of GM organisms and products listed
n the MOA’s GMO-catalog [42,44]. Presently cotton seeds, soy-
ean, corn, canola, tomato and their seeds, and a few products
erived from these crops such as soybean oil, corn flour and
omato paste are on the list [42]. All items listed in the GMO-
atalog that are for sale in China must be clearly labeled if they
ontain GM ingredient(s). For transgenic organisms and their
roducts, or seeds, livestock and poultry breeds, aquatic fry,
esticides, veterinary drugs, fertilizers and additives containing
hese GMOs or GMOs ingredients, a direct label such as “trans-
enic soybean” should be used. While for processed products
irectly derived from agricultural transgenic products, the label
ust indicate the name of the main raw materials containing GM
ngredients, for example, “soybean oil – transgenic soybean as
aw material”. Moreover, labeling is needed even if the GM
ngredient is no longer detectable in the final processed prod-
ct; the label should indicate that the product is manufactured
sing transgenic raw materials but no longer contains the GM
ngredient [42].
.3.2. General Administration of Quality Supervision,
nspection and Quarantine (AQSIQ)
AQSIQ is responsible for the inspection and quarantine of
mport and export of agricultural GMO products under the
QSIQ regulation [44]. Upon entry into China, the product‘s
wner or the owner’s agents should declare to AQSIQ whether
r not the importing product is transgenic and provide a copy of
iosafety certificate or relevant documents as proof [44]. AQSIQ
erifies all products declared to be transgenic using genetic tests.
hereas for non-transgenic products, AQSIQ conducts genetic
ests on a random sampling basis. AQSIQ may also test products
ot listed in the GMO-catalog. Products will be withdrawn or
estroyed if they are found to contain GM ingredients different
rom those declared.
For GMOs in transit, prior application with the AQSIQ and
fficial proof evidencing the approval of research or marketing
f the products issued by the exported country or region are
equired.
.4. Bt rice in China
Vast effort and resources from the Chinese government and
cientists have been invested on rice – the essential staple to Chi-
ese. Among the many locally developed transgenic rice, two
arieties named “Bt Shanyou 63” and “Huahui No. 1” received
biosafety certificate for commercial plantation within Hubei
rovince in 2009. Research demonstrated that Bt rice could ben-
fit farmers by a higher yield and decreased use of pesticides,
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hus could provide more food to feed the public, improve farm-
rs’ health and reduce the pollution arose from crop cultivations
4,31]. Up to date, no transgenic rice variety has obtained a
rop variety certificate and therefore no GM rice is available
o the public [31,35]. However, GM rice has been detected in
oth the local and exported markets. In Europe, after detecting
M contamination of rice from China time after time, the Euro-
ean Union has implemented emergency measures since 2012 to
mpose stricter inspection on rice products from China. In 2013,
he EU reported 25 incidences of GM contamination in the rice
mported from China mostly concerning “Bt Shanyou 63” [45].
Regulatory agencies do not perform genetic testing on rice
ecause the test is not required under the current national rice
tandard. Therefore stakeholders such as sellers, exporters and
onsumers would not be able to know whether the rice contains
M ingredient [46]. In 2014, the local media China Central Tele-
ision (CCTV) sampled five bags of rice from supermarket in
uhan city of Hubei province for genetic testing, revealed that
hree out of the five samples contained transgenic ingredient “Bt
hanyo 63” [46]. The developer of “Bt Shanyo 63” speculated
hat the GM seeds have probably leaked out during the prepro-
uction testing. In the same year, illegal large-scaled planting of
ransgenic rice and corn in four provinces were reported. Illegal
nvironment release testing, preproduction testing or production
ay account for the emergence of these unauthorized GM crops
47].
. Regulation in the U.S.
.1. Adoption of GM crops
United States is the country that grew the largest area of trans-
enic crops since 2010 [5]. The country alone grew 73.1 million
ectares of transgenic crops accounting for 40% of the global
ontributions in 2014. Adoption rate of transgenic crops is very
igh in the U.S. and keeps elevating, for example from 2013
o 2014, the adoption rate of soybean rose from 93% to 94%,
aize from 90% to 93%, and cotton from 90% to 96% [5].
mong the 357 GM events approved in the world as of October
014, the U.S. has approved 171 events (excluding stacking
vents), slightly fewer than the first ranking country Japan which
as granted 201 events. Currently, GM alfalfa, canola, corn,
otton, papaya, soybean, sugar beets and squash are commer-
ially cultivated in the U.S. [5]. Many of these crops are used to
roduce processed foods and strikingly more than 95% of food-
roducing animals are fed with GM foods [4]. With such a high
doption rate and coverage, it is not surprising that over 75%
f processed foods in the supermarkets contain GM ingredients
48].
.2. Legislation
Similar to China, there is no federal law specific for GMOs
r GM foods. GM organisms and foods are regulated by legis-
ations enacted for conventional products [6]. The U.S. is much
ore lenient to GMOs and GM foods than China and many other
ountries, probably because of the FDA’s premise that GM foods
6
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o not significantly differ from non-GM foods and hence, with-
ut a contrary evidence, GM foods are safe and do not require
articular safety assessment and labeling [4].
The U.S. adopts a voluntary labeling system for GM foods
lthough labeling is a top public concern. In a poll conducted
n 2013, 93% of respondents supported a mandatory labeling
f GM foods [49]. Under the U.S. legal system, a state could
xercise its discretion to pass their own law to regulate GM
oods absent conflict with the federal law [6]. Many states have
lready proposed bills to require GM food labeling. Among the
0 states, currently only three of them, Connecticut, Maine and
ermont passed their own legislation mandating GM food label-
ng during 2013–2014 [4]. The first two states require at least
our neighboring states to pass similar laws before actual imple-
entation of the labeling law. As of July 1, 2016, Vermont will
e the very first state to institute compulsory labeling of foods
roduced with or partially produced with genetic engineering.
At the federal level, both anti-labeling and pro-labeling bills
ave been proposed and discussed for years. In 2015, two
abeling bills “Safe and Accurate Food Labeling Act of 2015”
nd “Genetically Engineered Food Right-to-Know Act” were
ntroduced. The former prohibits states from demanding GM
ood labeling and does not require food producers to declare
se of genetic engineering solely because the food was devel-
ped with GE technology. This bill was passed in House on July
3, 2015 [50]; if enacted, this would preempt all existing state’s
M food labeling laws such as the Vermont Act 120. On the
ontrary, the latter bill requires whole or processed foods pro-
uced with GE or containing GE ingredients be labeled, and
rohibits the use of “natural” or similar words to advertise or
abel foods containing GE ingredients [51]. How the battle over
M food labeling is going is largely unpredictable for now, but
efinitely would bring a huge impact to the public regardless of
he outcome.
Some counties such as Maui County of Hawaii and Jack-
on and Josephine Counties of Oregon managed to restrict GM
rops cultivation. However, Maui’s ban was invalidated by the
ederal district court because the court ruled that the prohibition
s conflicted with the state law. While in Oregon, since Jack-
on is exempted from the state “right to farm” law which gives
he state sole discretion in regulating seeds, Jackson’s ban is
ot preempted by the state law and hence enforceable, whereas
osephine’s ban is likely to be challenged at the court [52].
Call for a tighter control over GM foods remains across the
ountry. On July 20, 2015, the U.S. government announced that
he government has recognized the need to review its regula-
ory framework over GM crops in view of the advances in the
echnology and change of product landscape, and admitted that
ts 30-year-old system is unclear and did not foster public confi-
ence [12]. A special task force will be set up for this mission and
he first year focus would be to clarify the products or product
reas responsible for each agency..3. Agency regulations
Three federal bodies, namely the U.S. Department of Agri-
ulture (USDA), the Environmental Protection Agency (EPA)
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nd the Food and Drug Administration (FDA) are in charge of
verseeing GMOs and GM food products.
.3.1. USDA – safe to grow?
The USDA takes the role of protecting the environment and
lants from agricultural pests, weeds and diseases. Introduction
f a GM plant to the U.S. is subject to prior approval from
he USDA. The subsidiary agency, Animal and Plant Health
nspection Service (APHIS), is responsible for approving and
onitoring biotech crops under the Plant Protection Act [53] and
egulations set forth in Title 7 of Code of Federal Regulations,
art 340 (7 C.F.R. §340) [54].
Under statutory definition, GM organisms that are plant pests
or potentially plant pests) and products containing these GMOs
re “regulated articles” subject to APHIS regulations. Hence,
PHIS has the authority to approve and police field testing,
lanting, import and interstate movement of most GM crops.
Three routes are available to introduce a regulated article to
he U.S.– (i) notification procedure, (ii) permit application and
iii) determination of nonregulated status [54].
(i) Notification procedure
As its name implies, this procedure notifies the APHIS
about the introduction of a GM crop without a permit.
Notification must be made 10 days before the interstate
movement, or 30 days before the importation or environ-
mental release. The APHIS will either acknowledge or deny
the notification within 10 days after receiving the applica-
tion for interstate movement, or 30 days for application for
importation or environmental release. If the APHIS denies
the notification, applicant may apply for a permit.
The regulated article must meet six requirements to be
eligible for the notification procedure (7 C.F.R §340.3).
Generally GM plant that is not listed as a noxious weed
under the PPA can opt for the notification procedure, pro-
vided that the expression of the introduced genetic material
does not result in any plant diseases, toxicity or virus. Infor-
mation about the nature of GM plant and the introduced
gene, destination facilities for movement or the field site
location for environmental release, size of the introduction
is required for the application.
If the introduction is an environmental release, field trials
must be conducted to show the GM plant would not harm
the plants, non-target organisms and the environment. Field
test reports must be submitted within six months after the
field test terminates. Acknowledgment to notification for
environmental release is valid for one year from the date
of introduction and can be renewed annually by submitting
additional notification to the APHIS.
(ii) Permit application
GM plants not meeting the criteria for a notification
procedure must apply for a permit. The permit procedure
is more rigorous requiring details about, among others,
the expression of the altered genetic material, the molec-
ular biology of the system (e.g. donor–recipient–vector)
for producing the GM plant, procedures and safeguards
for preventing contamination, release and dissemination
t
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in the production of the GM plant including the donor
and recipient organisms and vectors, as well as procedures
and safeguards for preventing the escape and dissemina-
tion of plant at each of the intended destinations, and final
disposition of the GM plant (7 C.F.R §340.4).
Application for an environmental release permit has to be
submitted 120 days before the proposed release, to which
the APHIS will respond within 30 days after receiving the
application. While for interstate movement or importation,
application 60 days in advance is required and the APHIS
will respond within 15 days. Permit for importation has
to be applied for each shipment of the article. If interstate
movement of multiple GM plants is desired, one may apply
for a single limited permit for the multiple regulated arti-
cles, and the permit would be valid for movement between
specified locations for one year. APHIS will grant a permit
if it determines that the regulated article would be prop-
erly maintained and disposed to prevent dissemination. If
allowed for conducting field tests, submission of test reports
is due six months after the end of the test.
iii) Determination of nonregulated status
After sufficient field testing, GM plants that are proven
not to pose a plant pest risk to health and the environ-
ment may petition for a nonregulated status with factual
grounds why the plant should not be regulated under 7
C.F.R. §340. Field test reports conducted under the permit
and notification procedures, and relevant experimental data
and literatures to support the request are required (7 C.F.R.
§340.6).
APHIS will publish the petition on the Federal Register
for public comments for 60 days. The APHIS will either
deny the petition, or approve the petition in whole or in part
within 180 days after the receipt of the petition. If granted a
nonregulated status, the GM plants is no longer considered
a regulated article and can be planted and moved without
APHIS oversight [55].
The first GM crop approved by the APHIS for commercial-
zation is FlavrSavr® tomato in 1994. As of September 2013,
he APHIS has granted more than 17,000 permits and notifica-
ions for environmental release of GMOs which are mostly GM
lants, while 96 out of 145 petitions for non-regulated status
ave been granted. Corn is the type of plant mostly approved
oth for environmental release and nonregulated status [55].
Furthermore, under the National Environmental Policy Act,
f the GM plant represents a new species or a new modification,
rior to making decisions about permits or nonregulated status,
he USDA needs to complete an environmental assessment (EA)
o determine whether the new plant release will affect the envi-
onment. Environmental impact statement (EIS) may be further
equired if the USDA finds the new plant significantly impacts
he environment [29].
The USDA does not actively monitor the approved GM
rops [29] but provides verification programs “Process Veri-
ed Program” and “Organic Certification” to food producers for
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ertifying their products with regard to their manufacturing or
andling processes.
.3.2. EPA – safe to the environment?
The EPA is in charge of overseeing the manufacture, sale and
se of all pesticides under the Federal Insecticide, Fungicide and
odenticide Act (FIFRA) [56]. The EPA also regulates microor-
anisms for commercial purposes under the Toxic Substances
ontrol Act (TSCA) since “chemical substance” is interpreted
o include microorganisms [57], while microorganisms that are
lant pests abide by the USDA regulations under the Plant Pro-
ection Act.
Not all transgenic plants are subject to EPA regulation unless
he plant is pesticidal in nature. Any substance that is intended
o control pests and to be produced and used in a living plant (or
n the produce of the plant) is identified as a “plant incorporated
rotectant (PIP)”. The FIFRA defines that PIP also includes
ny genetic material necessary for the production of the pes-
icide substance or any inert ingredient which is intentionally
ncluded in a pesticide product such as a selectable marker [58].
or instance a transgenic Bt crop, both the Bt protein and the gene
ncoding the Bt protein are subject to EPA pesticidal regulation.
Accordingly, the production of PIP-containing plant is regu-
ated by both the USDA and the EPA. What the EPA concerns is
he new pesticidal substances and its risk to human and the envi-
onment; while the USDA examines the entire plant and looks
nto the plant pest risk. The first PIP approved by the EPA is
ewLeaf potato in 1995 [29].
.3.2.1. PIP – tolerance and exemptions. PIPs are subject to
dditional regulations for their special properties. For pesticides
pplied to foods and animal feeds, the EPA sets a level of pesti-
ide that is safe for human and animal consumption. Leaning
n toxicity data and exposure data, the EPA determines the
mount of pesticide that may remain in or on foods that would
ose a low probability of risk to human health and the environ-
ent; “tolerance” is the maximum permissible level for pesticide
esidues allowed in or on commodities for human and animal
onsumption [59].
There are some circumstances that PIPs can be exempted
rom the formal registration. First, the EPA has absolved certain
ypes of PIP from the tolerance requirements because the agency
etermined that these PIPs meet the standard of “reasonable
ertainty of no harm” from dietary exposure to the pesticide
esidues. Therefore, no registration for a PIP-containing food
lant is required if the PIP residue is exempted from the tolerance
equirement. Currently a number of Bt proteins as expressed
n certain crops or in all type of plants are exempted from the
olerance requirement; nucleic acids that are part of the PIP are
lso exempted [59]. In addition, formal registration is waived if
he genetic material encoding the pesticidal substance is from a
lant that is sexually compatible with the recipient plant and is
ot derived from a sexually incompatible source, or if the PIP is
n approved inert ingredient from a sexually compatible plant
40 C.F.R. §174.2). Nonetheless, if exempted, the producer has
o report to the EPA any adverse effects within 30 days after the
ate of awareness of the events.
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.3.2.2. Experimental Use Permit. All new pesticides or regis-
ered pesticides for an unregistered use must be registered with
he EPA before their sale unless they are otherwise exempted.
ield test data is necessary for the registration. Developers may
pply for an “Experimental Use Permit” for conducting large
caled field tests so as to accumulate data for the new pesticide
r new use. Laboratory and greenhouse tests do not need a per-
it; while small scaled field tests involving less than 10 acres
f land or 1 acre of water only require a notification to the EPA
40 C.F.R. §172.3) [60].
.3.2.3. Registration. To register a pesticide with the EPA, the
pplicant needs to submit data demonstrating that the pesti-
ide will not pose any unreasonable risk to human health or
he environment when used according to label directions [58].
s for food plants containing PIPs, the level of pesticide residue
ust comply with the EPA tolerance standards. Basically, the
pplicant needs to establish the tolerance of pesticide residue,
nd submits data of field testing, insect resistant management
lan and a draft labeling. Apart from risks to human health,
on-target organisms and the environment, the EPA also looks
nto the potential of gene flow to other plants and the need for
nsect resistance management plans to prevent the development
f resistant pests [58]. A permit will be issued if the EPA finds
he foreign gene or protein is safe; however, if there is a chance
f gene flow as in the case of a Bt cotton, the EPA will restrict
he planting of the GM plant to reduce the risk. The EPA has so
ar approved 12 PIPs and 8 GM microbial pesticides [58].
.3.3. FDA – safe to eat?
.3.3.1. Food safety. The FDA regulates all food products
except meat, poultry and processed egg products which are
overned by the USDA), biological products and drugs [61]
nder the Federal Food, Drug and Cosmetic Act (FFDCA) [62].
ransgenic plants and transgenic animals are regulated distinctly
ecause transgenic animals are interpreted as veterinary drugs
nd hence subject to the drug provisions [6]. How the FDA
olices transgenic animals will be discussed shortly.
The FDA primarily monitors food safety by fighting against
ood adulteration and overseeing food additives (21 U.S.C.
342(a)(1)). Food containing any poisonous or deleterious sub-
tance that may render it deleterious to health is regarded as
dulterated and is prohibited from the introduction, delivery and
ale in the country. Generally, a pre-market approval of whole
ood or food products is unnecessary unless a food additive
xists.
Any substance that is intentionally added to food can be
lassified as either a food additive or a “Generally Recog-
ized as Safe (GRAS)” substance. A GRAS substance is a
ubstance considered safe by experts and thus does not require
pre-market review. In contrast, any food containing a food
dditive is regarded as unsafe and adulterated and cannot be
arketed without the FDA approval. Accordingly, a pre-marketpproval is mandatory only if the food contains a non-GRAS
ubstance or a food additive. Notably, the FDA is not respon-
ible for validating the GRAS status [63]. Instead, the agency
stablishes a voluntary GRAS notification program such that
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he food producer may claim the added substance is GRAS
nd supplement information supporting the GRAS assertion
29]. Unless there is any issue that leads the FDA to question
hether the use of the substance is GRAS, such substance is
xempted from the food additive approval process and can be
arketed without the FDA oversight. Hence, it is up to the food
roducer to market the GM foods directly, submit a GRAS noti-
cation to the FDA, or opt for the food additive route. So far only
ne GM crop, FlavrSavr® tomato, was reviewed and approved
s a food additive [29].
As early as 1992, the FDA stated clearly that is it not necessary
o specially regulate GM foods, noting that foods produced by
ioengineering do not present any different or greater safety con-
ern than foods developed by traditional plant breeding [64]. The
DA added that the agency “has rarely had occasion to review the
RAS status of foods derived from new plant varieties because
hese foods have been widely recognized and accepted as safe”.
he FDA reasoned that regulatory status of a food is irrespective
f its developing method’; instead is dependent upon objective
haracteristics of the food and the intended use of the food. Since
substances added to the food as a result of genetic modifica-
ion of the plant will be the same as or substantially similar to
ubstances commonly found in food” and these substances are
ubject to regulation as food additives if they are not GRAS, the
DA concluded that a premarket approval and labeling of GM
oods are not needed.
Accordingly, absent contrary evidence showing the expressed
roduct of a GM food is significantly different from the conven-
ional counterpart in terms of structure, function or compositions
hence subject to regulation as food additives), GM food can be
arketed without referencing it is produced by GE technology
64]. For instance a soybean expressing a peanut protein may
ave significant allergenic difference from the natural counter-
arts, therefore may require a pre-market approval.
6.3.3.1.1. Pre-market “ConsultationProcedures” for plants.
egardless of the FDA’s preposition that foods from GM plants
re safe, the agency established some voluntary “Consultation
rocedures” for new plant varieties in 1994 to encourage food
evelopers to consult the FDA on safety assessment and relevant
egulatory issues of the plant products. Food developers need to
ubmit a summary of the safety and nutritional assessment of
he plant including information about the new genetic trait and
ts effect, and any known or suspected toxicity and allergenicity
f the expressed products. The FDA stated clearly that it would
ot conduct a comprehensive scientific review of the developer’s
ata, but would consider whether there is any unresolved issue
hat needs FDA to institute further legal action [65]. If no out-
tanding regulatory or legal issue is found, the FDA will issue
letter acknowledging that a pre-market review is not required
ecause the developer has concluded that the new plant vari-
ty is not materially different from related foods and feeds on
he market. On its face, completion of the consultation process
oes not mean the FDA has verified the safety of GM plant for
onsumption.
Lately in 2015, the FDA noted that investigation into the sci-
ntific proof to ensure safety of foods would go beyond the
gency’s resources [66]. According to the director of FDA’s
T
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entre for Food Safety and Applied Nutrition, no company has
arketed GMO products without completing the FDA’s con-
ultation program although it is totally voluntary, but cautioned
hat overseas company may still import GM foods to the U.S.
ithout a pre-market review [67].
.3.3.2. Transgenic animals. The FDA has historically regu-
ated GM animals under the drug provisions as bound by the
tatutory definition. To commercially produce a GM animal,
eveloper needs to submit “New Animal Drug Application”
NADA) and provides data to demonstrate the GM animal is safe
nd effective for its intended use as required by 21 U.S.C. §360b
68,69]. GM animals generally require a pre-market approval via
ADA except those qualify for an investigational use such as
nimals for laboratory research. The FDA may also exercise its
iscretion to not require a NADA for GM animals of very low
isk such as GloFish® which is an aquarium fish genetically
ngineered to fluoresce in the dark [69].
The unique way of policing transgenic animals as drugs has
een criticized. Firstly, information are usually kept confidential
n the FDA’s drug approval process, therefore creating hurdle to
ublic to fully participate the regulatory process [29]. Another
uestion is that whether it is appropriate to adopt a drug standard
o evaluate a GM animal that is consumed as food.
On November 19, 2015, the FDA approved the first GM
nimal as human food, announced that the fast-growing AquAd-
atage salmon produced by AquaBounty Technologies is as safe
o eat and nutritious as non-GM Atlantic salmon [1]. The GM
almon is inserted with a growth hormone gene from Chinook
almon under the control of a promoter from ocean pout, and
rows faster than non-GM Atlantic salmon [70]. After a rigorous
valuation on the safety and effectiveness of the GM salmon, the
DA concluded that the inserted genes remained stable over all
enerations of fish, therefore the modification is safe for the fish
nd the food derived therefrom are safe for human and animal
onsumption. The agency also believes that the approval would
ot cause a significant impact to the environment, because the
pproved GM salmon can only be raised in two specific land-
ased facilities in Panama and Canada which are guarded with
ultiple containment measures to prevent the escape of eggs
nd fish and to make reproduction of the fish in wild extremely
ifficult [1]. Yet, to bring the GM salmon to the market, the pro-
ucer further needs an approval from the USDA for slaughter of
he fish.
.4. Labeling
.4.1. FDA labeling guidance
The FDA also oversees food labeling. Indication of GM ingre-
ients or GM status is wholly voluntary. Not until recently has
he FDA finalized its guidance on labeling foods derived from
enetically engineered plants [66] and concurrently drafted a
uidance on labeling foods derived from the GM salmon [71].
he FDA maintains its stance on voluntary labeling; food pro-
ucers may indicate whether their food products are derived
rom GM plants or salmon on their labels, provided that the
abeling is truthful and not misleading.
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The FDA provides a few examples illustrating that a truthful
abeling could be misleading. Like a product made largely of GM
orn flour while containing a small amount of oil derived from
on-GM soybean, a statement that “does not contain bioengi-
eered soybean oil” could be misleading because the consumer
ay believe that the entire or a larger portion of the product
s free of GM material. Also, the labeling should not contain
ny statement implying that the non-GM product is safer, more
utritious or has different attributes than other foods because the
roduct was not produced using modern biotechnology [66].
Notably, the FDA interprets that “genetic modification”
eans any alternation of genetic composition including
hose achieved through traditional hybridization or breeding
echniques, and therefore recommends using “genetically engi-
eered” or “modern biotechnology” rather than “genetically
odified” on food labels to indicate the food is developed using
ecombinant biotechnology [66]. If “genetically modified” is
sed, conjunction with “genetically engineered” or “modern
iotechnology” is recommended. Rather, the FDA recommends
sing statements such as “not genetically engineered”, “the oil
s made from soybeans that were not genetically engineered”
nd “we do not use Atlantic salmon produced using modern
iotechnology” to indicate that the food product is not derived
rom GMOs.
Moreover, the FDA cautions the use of statement such as
non-GMO” or “GMO free” for two reasons. Firstly, most foods
o not contain the entire organism and it is the organism rather
han the food being modified. Secondly, absent a regulatory def-
nition, the term “free” means zero or total absence which could
ender the claim misleading. For example, a statement “none of
he ingredients in this food is genetically engineered” is poten-
ially misleading if some ingredients such as salt are not capable
f being produced through bioengineering [66].
As for GM foods, the FDA gives examples such as “geneti-
ally engineered”, “this product contains cornmeal from corn
hat was produced using modern biotechnology” and “this
almon patty was made from Atlantic salmon produced using
odern biotechnology”. Special labeling is required if the GM
lant or salmon derived food is significantly different from the
on-GM counterparts in terms of its intended uses, consequences
f its uses, nutritional property or allergenicity [66,71].
.4.2. USDA veriﬁcation programs
Currently there is no governmental verification explicitly cer-
ifies a product as non-GMO. Food producers may request the
SDA to certify their products under “Process Verified Pro-
ram” or “Organic Certification” but neither of them necessarily
erifies a GMO-free or non-GM status of the product.
The first one “Process Verified Program” is an audit-
ng service provided by the Agricultural Marketing Services
AMS) for certifying labeling claims about the production,
andling or certain characteristics of the products. For exam-
le, company can request the AMS to certify their products
re non-GMO, or the products were made without antibiotics.
pon approval, companies can use the “USDA Process Verified”
hield and/or term on promotional materials for their products
72]. The “USDA Process Verified” shield can be used to certify
i
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MO-unrelated claims hence bearing the shield does not nec-
ssary mean the product is GMO-free [73].
The second one “Organic Certification” verifies that the prod-
ct is in compliance with the USDA organic standards under
C.F.R. Part 205. Products produced using GMOs cannot be
ertified as organic because the use of GMOs is prohibited in
rganic production and handling. The USDA may test for GM
ubstances if the agency believes GM technology was used to
roduce or handle the product. However, since GMOs commin-
ling or contamination may occur during processing, an organic
ertificate does not fully guarantee a GMO-free status; and the
nadvertent presence of GMOs in organic products would not
esult in the loss of organic status if the producers have taken
reventive measures to avoid GMO contact. Also, the Organic
ertification is not applicable for GMO-free products that were
roduced or handled by non-organic means [73].
Producers may also consider GMO-specific certification pro-
ided by non-governmental organizations such as Non-GMO
roject which issues a verified seal bearing a signature butter-
y logo. According to Non-GMO Project, many biggest food
ompanies are sourcing non-GMO ingredients, and many major
ompanies voluntarily state their products do not contain any
M ingredients or simply put the butterfly logo on the packaging
74].
.5. Post-market surveillance
While it is totally voluntary for producers to submit a GRAS
otification to the FDA, the safety of GM food could only rely
n the post-market surveillance on adulterated foods [29]. Con-
umers can raise inquires and complaints about the validity of
laims for foods to the FDA. The agency will take action to
nsure the validity of claims and works with the Federal Trade
ommission (FTC) in the case of advertising [63].
. Intellectual property protection
Intellectual property (IP) is an intangible but valuable asset
hat, if used strategically, can foster innovation and development
f a business. IP protects one’s innovation from unauthorized
ommercial exploitation and provides a market exclusivity that
ecures freedom to operate. Innovators can also raise funds using
heir IP through for example right transfer, licensing and mort-
age, or use IP to attract investment and collaboration.
IP can be of various forms. IP can be a right granted by
he government such as patent, trademark, industrial design and
opyright, a self-operating and self-policing protection like trade
ecret, and others. Each type of IP is different from each other in
erm of protectable subject matters, requirements and the scope
f protection. Acquiring proper IP rights is very crucial, requir-
ng preparation and action in the early stage of research, and
ontinuous procurement, evaluation and strategic planning dur-
ng the course of development. Every form of IP tools should be
horoughly considered to strike a comprehensive protection for
he creation and marketing advantages.
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.1. Basics of patent
Patent is probably the most fundamental tool to protect a
iotech invention. Patent is a right granted by the government
o exclude others from making, using, selling, offering for sale,
r importing an invention for a fixed period of time. Patent is
ot an automatic protection and requires individual application
n each country or region.
Each jurisdiction has its own patent system and requirements
ut the “first-to-file” rule is generally adopted. That means a
atent is granted to the first one who files a patent application
egardless of the date of invention. The term of protection is
sually 20 years from the effective date of filing the application.
o be entitled a patent, the invention must be a statutory patent-
ligible subject matter that is useful, novel and non-obvious. The
nvention must be fully described and enabled by the specifica-
ion [63]. Generally patent is eligible for compositions, products
articles of manufacture), methods (processes) and machines,
hile natural laws and abstract ideas are excluded. For instance,
ood ingredients, food products, production methods and appa-
atuses could be the subject of a patent. For GMOs, animal
nd plant varieties are not patentable in certain jurisdictions
uch as China and Europe, whilst microorganisms and cell lines
ther than human embryonic stem cells are typically patentable
75].
This article does not intend to discuss the patentability
equirements. Instead, the following sections highlight a few
atenting issues unique in China and the U.S. and discuss
ossible non-patent IP measures for protecting the GM food
echnology.
.1.1. Chinese patent landscape
.1.1.1. Patent-eligible subject matter. Invention patent in
hina is eligible for products, methods and machines. How-
ver, under Article 25 of the Patent Law, animal and plant
arieties as well as methods for the diagnosis and treatment of
iseases cannot be patented [76]. Although China disallows ani-
al and plant patents, methods for producing or breeding GM
nimals or plants are patentable (see e.g., CN101494969B and
N1620506B). Furthermore, components and axillary methods
or producing GM varieties such as genes, promoters and trans-
ormation methods are patentable. Nonetheless, as discussed
ater, breeders who want to acquire an exclusive right in their
lant varieties can apply for a new plant variety certificate from
he MOA.
.1.2. U.S. patent landscape
.1.2.1. Patent-eligible subject matter. Laws of nature, natural
henomena and abstract ideas have been historically excepted
rom the U.S. patent protection. The exclusion further extends
o natural matters and their uses in light of a few Supreme
ourt’s rulings about patent eligibility of natural matters such
s Myriad [77]. Myriad ruled that an isolated nucleic acid hav-
ng sequence identical to a breast cancer-related gene is not
atentable; whereas a complementary DNA (cDNA) having
on-coding introns of the gene removed is patentable because
he cDNA is distinct from the natural gene [77]. The decision
i
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mplies that nucleic acids having identical sequence to nat-
ral DNA are not patentable irrespective of its production
ethod. Since then, the U.S. Patent and Trademark Office
USPTO) holds that products such as nucleic acids and chem-
cals of natural origin, taken alone or in combination, are not
atentable unless the products exhibit markedly different char-
cteristics from the natural counterparts in terms of structure,
unction and/or other properties [78]. Absent a standard for
markedly different characteristics”, the USPTO will evaluate
he products based on what is recited in the claim on a case-by-
ase basis. The new examining policy also notes that general
ses or applications of natural products are not patentable;
or example, a method of treating breast cancer comprising
dministering to a patient an effective amount of a purified
atural compound is deemed eligible because the method prac-
ically applies the natural product to treat a particular disease
78].
.1.2.2. Plant patents vs utility patents. U.S. is one of the
ew jurisdictions practicing a plant patent system. By law,
lant patents protect asexually reproduced plants (cuttings and
unds) excluding tuber propagated plants [79]; while utility
atent is eligible for sexually reproduced plants (flowers and
eeds) including transgenic varieties. A plant patent is granted
o the entire plant. Utility patent is more versatile because it
ould widely cover traits, transformants, production methods
nd many other inventions associated with the GM technology.
oth plant patent and utility patent are entitled a patent term of
0 years. It is also possible to protect sexually reproduced or
uber propagated plant varieties through a plant variety protec-
ion certificate (PVPC) which is independent of plant and utility
atent [80].
.1.2.3. Patent exhaustion of patented GM seeds. Monsanto is
U.S. founded multinational company that is highly devoted
n biotech agrochemicals and agriculture. One major success
f the company is the invention of the herbicide Roundup®
nd a plurality of Roundup Ready® GM seeds engineered with
oundup®-resistant trait. The proprietary Roundup technology
as brought the company a considerable revenue from global
ale. The company holds U.S. patents on the Roundup tech-
ology and has actively exercised its patent right by suing
armers for infringement. Bowman is a notable case which
ooked into the issue of patent exhaustion of seed patents
81].
Monsanto sells its GM seeds with licensing agreements
estricting the farmers that they can only plant the GM seeds
or a single season, and forbidding the farmers to supply the
riginal seeds to others, or to save or sell to others the resulting
rops for replanting purposes.
InBowman, Monsanto sued farmer Bowman for infringing its
atent on Roundup® technology in 2007. Bowman bought com-
odity soybeans intended for consumption from a grain elevatorn 1999. These commodity soybeans are a mixture of soybeans
arvested by other farmers and some of them may have been
erived from Monsanto’s Roundup Ready® soybeans. Bow-
an planted the purchased commodity soybeans and sprayed
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lyphosate during the cultivation. He finally obtained a crop in
hat season and retained the harvested soybeans. By replanting
hese harvested soybeans in later seasons, Bowman obtained
ight crops in total [81].
It has long been held that a patent right in an item exhausts
pon an authorized sale of the item. The so-called “patent
xhaustion” or “first-sale doctrine” terminates the patent right
n a patented item upon initial authorized sale of the item, and
ence the purchaser can freely use or resell that purchased item
ithout bound by the patent [81]. Under the patent exhaustion
octrine, Monsanto has no control over the uses of its patented
eed upon sale.
During the court proceedings, Bowman raised the patent
xhaustion as a defense, argued that Monsanto’s right should
ave extinguished upon the authorized sale of its soybeans from
he local farmers to the grain elevator. Monsanto claimed that
he company’s restrictive sale prohibited the replanting activity.
herefore, the underlying question is whether the replanting and
arvesting activity of Bowman, who purchased soybeans from a
endor other than Monsanto has infringed Monsanto’s patents.
oth the district court and the appellant court held that Bowman
nfringed Monsanto’s patents, reasoned that patent exhaustion
rotects the “right to use” a patented article following an autho-
ized sale, but the “right to make” a patented article remains with
he patentee [81].
In 2013, the Supreme Court affirmed the appellant court’s
ecision and ruled in favor of Monsanto. According to the
ourt, Bowman may resell the purchased commodity soybeans
o others, consumed the soybeans himself or feed them to his
nimals, but the exhaustion doctrine does not enable Bowman
o make additional copies of the patented soybeans without
onsanto’s permission. The Court elaborated that other compa-
ies or farmers could purchase patented seeds from Monsanto,
nd then reproduce and sell the seeds; if the exhaustion doc-
rine protects the right to produce subsequent generations of the
rops, this would deprive Monsanto of its monopoly. As in the
ase of Bowman, Monsanto received no gain from Bowman’s
nnual production and sale of the Roundup Ready® soybeans
81].
The Judge ofBowman expressed that the court’s decision only
ddresses the specific case of Bowman. While whether Bowman
ould set a precedent for every self-replicating patented product
emains to be seen, it nonetheless upheld that patent owners
reserve their right in anew copies of the patented item despite
he copies are derived from a prior authorized sale. Therefore
ot just the agricultural industry, other biotech industries which
nvolve self-replicating products should be cautious about the
ssue of Bowman which could be far-reaching and significant to
heir business and practice.
. Non-patent IP protection
This section introduces plant breeder’s right and trade secret
hich are two common IP tools that are applicable for the GM
echnology. Regardless, others such as trademark, design and
randing should also be considered.
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.1. Plant breeder’s right
Plant breeder’s right is a patent-like protection for plant
arieties conferred based on the International Union for the
rotection of New Varieties of Plants (UPOV) Convention [80].
Plant breeder’s right provides a patent independent option for
rotecting plant species, hence is particularly useful in jurisdic-
ions that bar plant patents. The approval requirements are far
ess stringent than patent. In brief, developers need to provide
nformation showing the plant variety is new, distinct from other
arieties, uniform, and stable. A new variety means the propa-
ating material of the variety has not been sold for more than
ne year in the country of protection, or more than four years
or six years in the case of trees and vines) outside the country
f protection. Essentially, research uses or uses of the protected
ariety for breeding (i.e., developing) a new variety are exempted
rom infringement of the plant breeder’s right. More impor-
antly, farmers can grow and save seeds of the protected varieties
nd plant the harvested seeds at a later time in their own farms
ithout prior consent of the certificate holders [80].
In China, the plant breeder’s right is managed as a new plant
ariety certificate issued by the MOA (for agricultural plants)
nd the Ministry of Forestry (for forest plants). The term of pro-
ection is 20 years from the date of issuance of the certificate for
ines, forest trees, fruit trees and ornamental plants, and 15 years
or the others [82]. Certificate holders are entitled an exclusive
ight to commercially produce and sell the propagating material
f the protected variety, as well as the commercial production of
ther varieties which involve the use of the propagating material
n a repeated manner.
While in the U.S., the Plant Variety Protection Office (PVPO)
nder the USDA is responsible for issuing the plant variety pro-
ection certificate (PVPC). The term of protection is 20 years
or most plants except for vines and trees having 25 years. Apart
rom the right in commercial production and selling of the pro-
ected varieties and in uses of the protected varieties in producing
ther varieties, PVPC holders also enjoy an exclusive right in
mporting and exporting the protected varieties. Protection could
lso be extended to essentially derived varieties, indistinct vari-
ties and the harvested materials obtained through the use of
ropagating material of the protected variety [83]. Given that
atent does not provide any research, breeding or farmer exemp-
ions as the plant breeder’s right does, it is possible to exploit
oth patent and PVPC in the U.S. to maximize the protection.
.2. Trade secret
Trade secret is one form of IP which protects confidential
nformation against theft. Information that are useful in busi-
ess and possessing economic value can be the subject of trade
ecret. Unlike patent which encourages sharing of information
nd mandates disclosure of an invention, secrecy is essential
or a trade secret protection. Trade secret owner must make
easonable effort to maintain secrecy of the information. The
oca-Cola® formula is the most famous example of trade secret
hat has been held for years.
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Table 1
Major differences between patents and trade secrets.
Patents Trade secrets
1 Exclusive right Yes. Prevents unauthorized production, use, sale and import
of inventions.
No. Only prevents acquisition of trade
secrets by improper means.
2 Protectable subject matters Useful, new and non-obvious compositions, processes,
machines and manufactures.
Virtually everything.
3 Disclosure Full disclosure on how to make and use the invention at the
time of filing.
Kept confidential.
4 Effective time for protection Upon approval of patent which can take >3 years for most
biotech inventions.
Immediate protection.
5 Duration 20 years from filing date. Perpetual term until it is disclosed, reverse
engineered, or independently developed.
6 Cost Filing, prosecution, maintenance and attorney fees. Costs for maintaining secrecy.
7 Risks Loss of right if patent is invalidated or held unenforceable.
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Trade secret and patent are frequently regarded as mutually
xclusive. Indeed there are many difference between trade secret
nd patent (Table 1) but in fact they can be used in conjunction to
enerate synergistic effects [84]. It should be emphasized that
rade secret serves to prevent improper acquisition and use of
onfidential information, and does not represent an exclusive
ight in using the information. As a general guidance, below
xplores a host of factors that may affect the choice between
atent and trade secret protection.
.2.1. Patent vs trade secret
.2.1.1. Protectable subject matter. Trade secret does not have
o be patentable. Theoretically all forms of invention can be
aintained as trade secret. Apart from substantive parts of
he technology (e.g. genes, breeding methods and manufac-
uring methods, devices), knowledge or experience related to
he technology (“know-how”) or even matters irrelevant to the
echnology (e.g. customer lists) can be the subject of trade secret.
Trade secret is a good option for protecting subject matters
hat are not patent-eligible, such as natural products in the U.S.
nd treatment methods in China. Patentability of the technology
nd the possible scope of patent protection must be fully eval-
ated. Inventions that are not novel or inventive may better be
rotected as trade secret.
.2.1.2. Disclosure. Patent requires a full disclosure about how
o make and use an invention. The information is exposed to
he public domain upon publication of the application even if
patent is not ultimately awarded. Disclosure of the technical
nformation may facilitate competitors and hence undermine the
ompetitive advantages.
.2.1.3. Effective term for protection. Patent right in an inven-
ion runs into effect upon issuance of the patent and vanishes
n the expiry date of the patent. While for trade secret, protec-
ion commences immediately and stands till the information is
isclosed or otherwise independently obtained.
.2.1.4. Costs. Subject to actual circumstance, costs for patent
nd trade secret can be comparable or highly different. Patent
s
i
n
ntent law or legal reverse engineering and independent
development.
equires a substantial amount of fees for application, mainte-
ance and attorney service. Maintaining a trade secret may,
mong other things, involve access control over computers and
ocuments, non-disclosure agreements (NDA) with employees
nd collaborators, guidelines for confidentiality and so on. Costs
or trade secret can be very high to set up a high level of con-
dentiality. While it is worth noting that for a fast-evolving
echnology which gets outdated quickly and replaced by newer
reations, a 20-year patent term to one single invention may not
e necessary. Instead, the innovator may put resources in fil-
ng new applications for follow-on generations of the invention.
t may be more cost-effective for startups or small enterprises
o pursue patents for their core and groundbreaking technology
hile protecting the subsequent modifications as trade secret.
.2.1.5. Enforcement and risks. Getting a patent does not guar-
ntee a protection for an invention because patent can be
nvalidated or held unenforceable. Validity of patent is suscep-
ible to change in patent law and regulations. For example, the
ver patent-eligible business method and isolated genes are now
o longer patentable in the U.S. In common law jurisdictions in
hich the courts are usually bound to follow decisions of legal
recedents, patentability standards could change now and then
hus affecting the patent validity and jeopardizing right of the
atent owners.
It is not uncommon that potential infringers or stakeholders
hallenge a patent on the ground of patentability or inequitable
onducts through litigations or post-grant proceedings. Some
r all of the claims, upon re-examination by the court or the
atent office, may be held invalid or unenforceable. On the other
and, determination of infringement is never an easy task and is
redominantly based on how the claim language is interpreted.
lainly, every element in the claims of the infringed patent or its
ubstantial equivalent must be found in the accused invention to
onstitute an infringement.
Not every invention is suitable to be protected as a trade
ecret. Trade secret does not preclude a third party from obtain-
ng and using the information by fair means. Hence, innovators
eed to consider how easily their inventions be reversed engi-
eered or developed independently. For instance, a device on
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ublic sale may risk reverse-engineering and hence may opt for
patent protection instead. Notwithstanding patent can preserve
ight in an invention upon independent discovery of the inven-
ion, protection could still be ineffective if the invention can be
asily designed around.
.2.1.6. Prior use exemption. Prior use exemption creates a
afe harbor to any third party who independently developed
nd uses a patented invention before a prescribed time by
xempting the party from charges of patent infringement. China,
.S., Australia, Canada, Japan, Korea and many other countries
rovide exemption for prior commercial uses. Generally there
re two limitations in the exemption: (1) prior users cannot
xtend their uses beyond the original scope of the prior com-
ercial use; and (2) the exemption is not transferable unless the
ransfer is done in connection with the entire, or at least part of
he, business (it is freely assignable in Australia) [85].
In the U.S., prior use exemption includes commercial
xploitation of patented processes, or commercial uses of
atented machines, manufactures or compositions. The prior
ses must occur at least one year before the earlier of the effec-
ive filing date of the patent application or the date of public
isclosure of the invention. Also, the exemption is limited to
ses at sites where the invention was initially used. The exemp-
ion further encompasses non-commercial uses by non-profit
esearch laboratory or entities, and uses for the purpose of pre-
arket regulatory review. Notably, the prior use defense cannot
e used against patents owned by or assigned to universities and
heir affiliates, meaning that a person could still be liable for
nfringement if the patent involved is held by a university [86].
In China, practice of a patented method or manufacture of a
atented product before the date of patent application is qualified
or a prior use exemption. The exemption is also applicable if
he users have already made necessary preparations for the use
r manufacture. The prior user can continue to use the patented
ethod or make the patented product within the original scope
f the prior use. The exemption is also eligible for uses for the
urpose of premarket regulatory review or research [76].
Unlike most forms of IP, the prior use exemption cannot be
ransferred, assigned or licensed to others but it is transferable
f the transfer is made together with the entire business (China
nd U.S.) or the line of the business (U.S.).
.2.2. Patent or trade secret?
In short, patent and trade secret have their pros and cons and
re not mutually exclusive. Patent requires vast effort in for-
ulating strategy, prosecution and policing. Trade secret must
nstitute adequate measures to prevent inadvertent or intentional
isclosure because exposure of the information could be fatal to
business.
It is advised to regularly evaluate the relative strength and
eakness of patent and trade secret for each invention as theechnology evolves. Also, it is not necessary to protect the entire
echnology using either patent or trade secret. Some aspects such
s compositions may be protected by patent while manufacturing
ethods or know-how could be maintained as trade secret. And Human Wellness 5 (2016) 124–140
ybrid approach could generate synergetic benefits than the sum
f the two options.
While the best strategy needs to be determined case-by-case,
t is generally recommend to file a patent application for ground-
reaking or core technology that is crucial to the business. For
ubsequent improvements or optimizations, innovator may file
U.S. provisional patent application to secure an earliest fil-
ng date while buying time to evaluate the patentability of the
nvention [63]. A provisional application does not grant any
atent right, and a regular application must be filed within a
ear after the filing date of the provisional application if the
nnovator decides to protect the invention using patent. On the
ontrary, if opt for a trade secret protection, the invention will not
e disclosed since the provisional application goes abandoned
utomatically after 12 months and is never published.
. Conclusion
Use of genetic engineering in food industries is deemed
nevitable under the strong wave of biotechnology. Agricul-
ural biotechnology has already achieved a great commercial
uccess. Foods derived from GM crops or GM-crops fed ani-
als are readily available in the market and more GM foods are
xpected to hit the market. While it may be beyond the gov-
rnment’s ability and authority to assure safety of every GM
ood before its marketing, the public call for GM labeling is
ational and deserves attention and actions. The Chinese and
.S. government have promised to revisit their regulations for
M organisms and products. New law or regulation is at sight
nd could significantly influence the development and commer-
ialization of GM foods. Intellectual property is another factor
eterminative in the success of the business. Innovators and
he industries need to watchfully monitor the regulatory and
P landscapes, adapt to the evolving policy, and work with expe-
ienced professionals to map out a realistic strategy for moving
he business forward.
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